Lepowsky Eric, Ghaderinezhad Fariba, Knowlton Stephanie, Tasoglu Savas
Department of Mechanical Engineering, University of Connecticut, Storrs, Connecticut 06269, USA.
Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut 06269, USA.
Biomicrofluidics. 2017 Oct 17;11(5):051501. doi: 10.1063/1.4996768. eCollection 2017 Sep.
A transformation of the healthcare industry is necessary and imminent: hospital-centered, reactive care will soon give way to proactive, person-centered care which focuses on individuals' well-being. However, this transition will only be made possible through scientific innovation. Next-generation technologies will be the key to developing affordable and accessible care, while also lowering the costs of healthcare. A promising solution to this challenge is low-cost continuous health monitoring; this approach allows for effective screening, analysis, and diagnosis and facilitates proactive medical intervention. Urine has great promise for being a key resource for health monitoring; unlike blood, it can be collected effortlessly on a daily basis without pain or the need for special equipment. Unfortunately, the commercial rapid urine analysis tests that exist today can only go so far-this is where the promise of microfluidic devices lies. Microfluidic devices have a proven record of being effective analytical devices, capable of controlling the flow of fluid samples, containing reaction and detection zones, and displaying results, all within a compact footprint. Moving past traditional glass- and polymer-based microfluidics, paper-based microfluidic devices possess the same diagnostic ability, with the added benefits of facile manufacturing, low-cost implementation, and disposability. Hence, we review the recent progress in the application of paper-based microfluidics to urine analysis as a solution to providing continuous health monitoring for proactive care. First, we present important considerations for point-of-care diagnostic devices. We then discuss what urine is and how paper functions as the substrate for urine analysis. Next, we cover the current commercial rapid tests that exist and thereby demonstrate where paper-based microfluidic urine analysis devices may fit into the commercial market in the future. Afterward, we discuss various fabrication techniques that have been recently developed for paper-based microfluidic devices. Transitioning from fabrication to implementation, we present some of the clinically implemented urine assays and their importance in healthcare and clinical diagnosis, with a focus on paper-based microfluidic assays. We then conclude by providing an overview of select biomarker research tailored towards urine diagnostics. This review will demonstrate the applicability of paper-based assays for urine analysis and where they may fit into the commercial healthcare market.
以医院为中心的被动式医疗将很快让位于以患者为中心的主动式医疗,后者关注个人的健康福祉。然而,这一转变只有通过科技创新才能实现。下一代技术将是发展可负担得起且可及的医疗服务的关键,同时还能降低医疗成本。应对这一挑战的一个有前景的解决方案是低成本的连续健康监测;这种方法能够实现有效的筛查、分析和诊断,并促进主动的医疗干预。尿液有望成为健康监测的关键资源;与血液不同,它可以每天轻松采集,无需痛苦,也无需特殊设备。不幸的是,目前现有的商用快速尿液分析测试功能有限——这正是微流控设备的潜力所在。微流控设备作为有效的分析设备已有成功记录,能够在紧凑的空间内控制流体样本的流动、包含反应和检测区域并显示结果。超越传统的基于玻璃和聚合物的微流控技术,基于纸的微流控设备具备相同的诊断能力,还具有易于制造、低成本实现和可一次性使用的额外优势。因此,我们综述了基于纸的微流控技术在尿液分析中的应用进展,作为为主动式医疗提供连续健康监测的一种解决方案。首先,我们阐述了即时诊断设备的重要考量因素。然后我们讨论尿液是什么以及纸如何作为尿液分析的基质发挥作用。接下来,我们介绍现有的商用快速测试,从而说明基于纸的微流控尿液分析设备未来在商业市场中的定位。之后,我们讨论最近为基于纸的微流控设备开发的各种制造技术。从制造过渡到应用,我们介绍一些已在临床应用的尿液检测方法及其在医疗保健和临床诊断中的重要性,重点是基于纸的微流控检测方法。然后我们通过概述针对尿液诊断的特定生物标志物研究来得出结论。本综述将展示基于纸的检测方法在尿液分析中的适用性以及它们在商业医疗市场中的定位。